Author Interview - Professor Andrew Cope, 2026
The IMID Forum
- Published
- March 5, 2026
- Duration
- 24:50
- Summary source
- description
- Last updated
- Jun 21, 2026
Discusses Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Andrew Cope from t…
Summary
Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Andrew Cope from the Centre for Rheumatic Diseases, King’s College London, London, UK, as they discuss his recent paper ‘Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial’.
Intelligent report
Sign in to read teasers, or upgrade to Research Pro to commission a new dossier for this episode. Learn more →
Show notes
Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Andrew Cope from the Centre for Rheumatic Diseases, King’s College London, London, UK, as they discuss his recent paper ‘Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial’.